INBX — Inhibrx Biosciences Inc. stock price, charts and financials

Latest market price

104.73

+2.96+2.91%

Overview Short InterestFilings

INBXQT62Inhibrx Biosciences Inc.·NASDAQ

Overview Short InterestFilings

104.73+2.91%

News

Up 2.9% — Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors? (fool.com).

Medium confidence

Loading chart...

Signal & projected range

Insider open-market buyHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

MESO+3.19%$14.87 FTRE+1.55%$20.28 NKTR+1.45%$68.36 GHRS+3.50%$28.72 RAPP+1.35%$41.95 AGIO+2.00%$33.61 ZBIO-1.08%$31.97 GPCR-1.13%$35.10

Snapshot

Index	-	P/E	-	EPS (ttm)	-1.51	Insider Own	-	Shs Outstand	14.67M	Perf Week	-6.00%

Market Cap	1.54B	Forward P/E	-	EPS next Y	-8.94	Insider Trans	0.18%	Shs Float	10.87M	Perf Month	10.68%

Enterprise Value	1.41B	PEG	-	EPS next Q	-2.45	Inst Own	-	Short Float	30.34%	Perf Quarter	11.18%

Income	-111.00M	P/S	192.06	EPS this Y	-530.24%	Inst Trans	-	Short Ratio	10.90	Perf Half Y	52.47%

Sales	8.00M	P/B	-	EPS next Y	6.09%	ROA	-89.60%	Short Interest	3.30M	Perf YTD	32.57%

Book/sh	-3.61	P/C	11.55	EPS next 5Y	-	ROE	1893.60%	52W High	155.29 -32.56%	Perf Year	294.17%

Cash/sh	9.07	P/FCF	-	EPS past 3/5Y	-	ROIC	-99.35%	52W Low	26.19 299.89%	Perf 3Y	-

Dividend Est.	0.85 (0.81%)	EV/EBITDA	-	Sales past 3/5Y	-20.63% -40.13%	Gross Margin	0.00%	Volatility	5.37% 7.86%	Perf 5Y	-

Dividend TTM	-	EV/Sales	176.06	EPS Y/Y TTM	-101.30%	Oper. Margin	0.00%	ATR (14)	8.24	Perf 10Y	-

Dividend Ex-Date	May 30, 2024	Quick Ratio	5.07	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	45.74	Recom	2.40

Dividend Gr. 3/5Y	-	Current Ratio	5.07	EPS Q/Q	-26.49%	SMA20	-8.67%	Beta	2.53	Target Price	285.00

Payout	0.00%	Debt/Eq	13.38	Sales Q/Q	-100.00%	SMA50	5.63%	Rel Volume	0.68	Prev Close	101.77

Employees	110	LT Debt/Eq	13.13	Earnings	Nov 13	SMA200	16.31%	Avg Volume	316.11K	Price	104.73

IPO Date	May 29, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.63% -	Net Debt/EBITDA	1.06	Volume	215,669	Change	2.91%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-24-26	Initiated	H.C	Buy	$245
May-15-26	Reiterated	Stifel Nicolaus		$300 → $325
Jan-23-24	Downgrade	JMP Securities	Market Outperform → Market Perform

Latest News· Times ET

Sep-15-26

Sep-15-2604:09PM

Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?fool.com

Sep-14-26

Sep-14-2605:46AM

Inhibrx: 'Strong Buy' Maintained With Ozekibart Action Date On The Horizon And Study Win With INBRX-106seekingalpha.com

Sep-09-26

Sep-09-2604:10AM

Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathomseekingalpha.com

Sep-08-26

Sep-08-2607:29AM

Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Ratesbenzinga.com

04:19AM

Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer studyreuters.com

03:30AM

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Studyprnewswire.com

Sep-04-26

Sep-04-2612:00PM

Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Studyprnewswire.com

Aug-24-26

Aug-24-2602:21AM

HC Wainwright & Co. Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $245Benzinga

Aug-13-26

Aug-13-2612:04PM

Inhibrx Reports Second Quarter 2026 Financial Resultsprnewswire.com

Jul-25-26

Jul-25-2605:36AM

Inhibrx Biosciences: The Whole Story Rides On INBRX-106SeekingAlpha

Jul-17-26

Jul-17-2602:43AM

Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening ActSeekingAlpha

Jul-16-26

Jul-16-2605:00AM

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Millionprnewswire.com

Jul-09-26

Jul-09-2609:01AM

Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choicezacks.com

Jun-15-26

Jun-15-2609:15AM

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional ChondrosarcomaYahoo

05:19AM

Inhibrx Biosciences Says FDA Accepts BLA Seeking Approval Of Ozekibart In Patients With Conventional Chondrosarcoma; PDUFA Goal Date Set For April 14, 2027Benzinga

Company

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	8	1	0	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	4	2	2	—	—	—	—	—	—
Gross Profit	4	-1	-2	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	16	23	128	—	—	—	—	—	—
Research and Development	92	113	204	—	—	—	—	—	—
Other Operating Expense	-1	-2	-3	—	—	—	—	—	—
Operating Income	-102	-135	-331	—	—	—	—	—	—
Interest Expense	9	12	13	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	0	7	2,033	—	—	—	—	—	—
Net Income Before Taxes	-111	-140	1,688	—	—	—	—	—	—
Income Taxes	0	0	0	—	—	—	—	—	—
Consolidated Net Income	-111	-140	1,688	—	—	—	—	—	—
Net Income From Continuing Operations	-111	-140	1,688	—	—	—	—	—	—
Net Income	-111	-140	1,688	—	—	—	—	—	—
EPS (Recurring)	-1.51	-9.04	116.58	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-1.51	-9.04	116.58	—	—	—	—	—	—
EPS (Diluted)	-1.51	-9.04	116.58	—	—	—	—	—	—
EBITDA	-101	-125	1,703	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	0.13	—	—	—	—	—	—
Price To Sales Ratio	510.56	1,185.00	—	—	—	—	—	—	—
Gross Margin	50.00	-100.00	—	—	—	—	—	—	—
Operating Margin	-1,275.00	-13,500.00	—	—	—	—	—	—	—
Net Margin	-1,387.50	-14,000.00	—	—	—	—	—	—	—
Shares Outstanding	39	15	14	—	—	—	—	—	—
Market Capitalization	4,084	1,185	216	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kayyem Jon Faiz	Director	Sep 16 '26	Buy	100.00	5,000	500,000	429,360	Sep 17
MANHARD KIMBERLY	Director	Sep 15 '26	Sale	105.05	500	52,525	7,500	Sep 15
MANHARD KIMBERLY	Director	Sep 14 '26	Sale	110.26	500	55,130	8,000	Sep 15
MANHARD KIMBERLY	Director	Sep 11 '26	Sale	111.78	500	55,888	8,500	Sep 15
MANHARD KIMBERLY	Director	Sep 09 '26	Sale	115.80	500	57,898	9,000	Sep 10
MANHARD KIMBERLY	Director	Sep 08 '26	Sale	115.14	500	57,570	9,500	Sep 10
Lappe Mark	Chief Executive Officer	Sep 08 '26	Buy	105.82	25,000	2,645,399	730,548	Sep 08
Kayyem Jon Faiz	Director	Sep 08 '26	Buy	113.52	5,000	567,580	424,360	Sep 08
FORSYTH DOUGLAS	Director	Sep 08 '26	Buy	114.65	2,500	286,617	227,064	Sep 08
VIKING GLOBAL INVESTORS LP	10% Owner	Oct 07 '25	Sale	32.25	350,000	11,287,501	67,018	Oct 09
Kayyem Jon Faiz	Director	Nov 20 '24	Buy	14.19	18,750	266,102	69,843	Nov 22
Kayyem Jon Faiz	Director	Nov 19 '24	Buy	14.23	34,843	495,708	51,093	Nov 22
Vuori Kristiina MD	Director	Oct 03 '24	Buy	15.00	6,667	100,005	20,443	Oct 07
Lappe Mark	Chief Executive Officer	Sep 16 '24	Buy	17.13	13,037	223,324	705,548	Sep 16
Lappe Mark	Chief Executive Officer	Sep 12 '24	Buy	15.05	26,963	405,793	692,511	Sep 16

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.